SEC Form 4 · accession 0001209191-18-041306
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cavan M. Redmond
Director
Period of report
Jul 1, 2018
Accepted (ET)
Jul 3, 2018 · 6:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common SharesF1 | $2.06 | Jul 1, 2018 | A | 40,000 | A | — | Jun 30, 2023 | Common Shares | 40,000 | 40,000 | D |
| Option to Purchase Common SharesF2 | $2.64 | holding | — | — | — | — | Feb 20, 2023 | Common Shares | 60,000 | 60,000 | D |
Explanation of responses
- F1Will become exercisable on June 30, 2019, based upon continued service on the board of directors.
- F2Will become exercisable on February 21, 2019, based upon continued service on the board of directors.